Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers (clinicaltrials.gov) - May 27, 2020 - P1; N=15; Not yet recruiting; Sponsor: UBP Greater China (Shanghai) Co., Ltd
Clinical • New P1 trial • Dermatology • Dermatopathology • Immunology • Urticaria
|